stockrowSAB Biotherapeutics, Inc.
SABS Healthcare Biotechnology
SAB Biotherapeutics, Inc.’s revenue for fiscal 2024 (year ended December 2024) was $1.3 million, down 40.9% from fiscal 2023.
- Revenue
- −91.0%
- EPS
- +74.3%
- Free cash flow
- −59.8%
- Total debt
- −5.01%
Quarter to June 2026, against a year earlier
Follow SABS
Alert me
SAB Biotherapeutics, Inc. (SABS) EV/Sales
As of 6 November 2026, SAB Biotherapeutics, Inc. (SABS) trades at a EV/Sales of 85.8×. Over the past ten years it has ranged from −53.2× (October 2025) to 133× (July 2026); the current reading is higher than 95% of that period. That is above the Biotechnology industry median of 9.0× and above the Healthcare sector median of 3.6×.
EV/Sales, daily
Embed this chart
Annual newest first
| Period | EV/Sales | Change |
|---|---|---|
| FY2024 | 10.8× | — |
| FY2023 | −6.5× | — |
| FY2022 | 0.7× | (75.04%) |
| FY2021 | 2.9× | — |
| FY2020 | 0.0× | — |
Quarterly newest first
| Period | EV/Sales | Change |
|---|---|---|
| Dec 2024 | 10.8× | — |
| Jun 2024 | −2.1× | — |
| Mar 2024 | −0.4× | — |
| Dec 2023 | −6.5× | — |
| 11 more quarters | Free account |
Against its own ten years
EV/Sales against peers
| Company | EV/Sales |
|---|---|
| QTTB Q32 Bio Inc. compare | −13.6× |
| TTRX Turn Therapeutics Inc. compare | n/m |
| VOGX Vogenx Inc compare | n/m |
| NAUT Nautilus Biotechnology, Inc. compare | n/m |
| RCKT Rocket Pharmaceuticals, Inc. compare | n/m |
| IPSC Century Therapeutics, Inc. compare | 2.0× |
| SPRY ARS Pharmaceuticals, Inc. compare | 2.6× |
| ARCT Arcturus Therapeutics Holdings Inc. compare | 6.0× |
| SABS SAB Biotherapeutics, Inc. | 85.8× |
| Biotechnology industry median | 9.0× |
| Healthcare sector median | 3.6× |
| Market median | 2.1× |
What EV/Sales is
EV/Sales tells an investor how the value of a whole company, counting its debt and cash, compares with the sales it brings in.
((Stock Price × Shares (Basic, Weighted) (latest quarter)) + (Long Term Debt (Total) (latest quarter) + Current Part of Debt (latest quarter)) − Cash & Short Term Investments (latest quarter)) ÷ Revenue (TTM)